NGAL has demonstrated predictive value for adverse outcomes in acute myocardial infarction (AMI) and heart failure (HF), suggesting its potential as a valuable biomarker for broader cardiovascular risk stratification. The gene discussed is LCN2; the disease is acute myocardial infarction.